top of page
Blue-Swirl-High-Res Mirror Right.jpg
Professor Teoh Swee Hin

About the Company:

Osteopore International is a Singapore based medical device company that design, develop, manufacture and distribute 3D printed bioresorbable implants.


The technology combines the science of Tissue Engineering and Regenerative Medicine with 3D printing to produce implantable scaffolds with a biomimetic microarchitecture that enable the body to regenerate tissue such as bone. We collaborate with clinicians and researchers internationally to develop products that address unmet clinical needs, reduce healthcare cost, improve patient outcomes and enhance lives.


Osteopore’s implants are synthetic (not from animal or human source), made from a polymer, polycaprolactone, that gradually resorb by the body over 18-24 months, breaking down into water and carbon dioxide. The bioresorbable and proprietary biomimetic structure of the implant enables patient to naturally regrow bone across large defect while the implant naturally degrades in tandem. By replacing permanent implant eliminates the need for additional surgeries to remove implants and avoid complications associated with permanent implants. We have demonstrated tissue regeneration in our patients with more than 150 published papers covering our technology and nearly 30 published papers regarding the clinical benefits and outcomes of our technology.


Osteopore’s technology is clinically validated with an implantation record of over 100,000 implants globally. Osteopore's strategic expansion into international markets covering every continent positions it as a key player in the global regenerative medicine landscape. The company's proactive approach to secure regulatory approvals in Tier 1 markets including FDA (US), CE Mark (EU.), TGA (AU.) and HSA (SG.) enhances its growth potential and broadens its reach, offering investors exposure to a diversified revenue stream.


With a commitment to transforming patient outcomes and advancing the field of medical technology, Osteopore is poised to make a lasting impact on the healthcare industry as the company continues to push the boundaries into surgical specialties with regenerative medicine.


List of Patents:

• US6730252

• US7968026

• US8071007

• EP691726B1

• US9492279

• KR101726885B1

• US8702808

• SG195588A1


Osteopore International Pte Ltd





+65 6250 2817




2 Tukang Innovation Grove,
JTC MedTech Hub,
Singapore 618305

Professor Teoh Swee Hin
"Osteopore believes that medical technology should deliver sustainable clinical outcome that improves the quality of life for patients and reduces overall healthcare expenses for all payers."

About the

Founder / Director:

Professor Teoh Swee Hin's journey is a testament to a lifetime dedicated to pioneering research and transformative leadership in multidisciplinary fields. Currently holding the distinguished position of Yuelu Professor at the College of Materials Science and Engineering, Hunan University, China, he also serves as an Emeritus Professor at Nanyang Technological University (NTU), enriching the School of Chemistry, Chemical Engineering and Biotechnology (SCCEB). He previously was among the earliest to hold joint appointment with the School of Chemical and Biomedical Engineering (SCBE) and the Lee Kong Chian School of Medicine (LKC Med) and the first Chief Engineer of the Skin Research Institute of Singapore. In recognition of his exceptional interdisciplinary research, educational and administrative leadership, Professor Teoh Swee Hin was honoured with the President’s Chair award from SCBE. His eminence extends to being recognized as a distinguished Fellow of the Academy of Engineers Singapore, solidifying his place among the elite in the engineering community.


Delving into the realm of innovation, Professor Teoh stands as a global trailblazer in the application of 3D printing technology for clinical scaffolds. His contributions were celebrated with accolades such as the "Golden Innovation Award" from the Far East Economic Review and the "Prestigious Engineering Achievement Award" from the Institute of Engineers in 2004. These recognitions specifically acknowledge his entrepreneurship in development of platform technology for scaffolds in bone tissue engineering.


In 2015, Professor Teoh received the "Special Award for Scientific Life-Time Achievement in Bone Tissue Engineering" at Bone-Tec in Stuttgart and his profile further soared during the SG50 celebrations, where he was prominently featured as one of Singapore's scientific pioneers in the book titled "Singapore’s Scientific Pioneers."


Continuing his legacy, Professor Teoh and his team were honoured with the "Patent for Good Award 2018" by the Intellectual Property Office of Singapore. Presently, his research endeavours are centered around regenerative medicine, spanning from novel biomaterials such as piezoelectric biomaterials, tissue engineering for bones and skin to biomimetic bioreactors, fish collagen, decellularized organs, and instrumented chick embryo for rapid biocompatibility screen of drugs/materials in early developmental stages in medical devices.


Beyond his pioneering research, Professor Teoh's commitment to education is evident. He held the pivotal role of Co-Chair (2001-2005) for the NUS Graduate Programme in Bioengineering, playing a crucial role in advancing knowledge and leadership in biomedical engineering research by educating the first batch of bioengineering postgraduate students in Singapore. Recognised for his exceptional teaching abilities, he has been honoured with numerous "Excellent Teaching Awards” and received the prestigious NTU Koh Boon Hwee Scholars Faculty Nominee Award of 2017, a testament to his unparalleled ability to inspire students beyond their perceived capabilities.



bottom of page